CCM
NBIX icon

Cadian Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Cadian Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-200,000
Closed -$7.96M – 112
2015
Q3 		$7.96M Buy
+200,000
New +$9.67M 0.29% 60

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Cadian Capital Management's NBIX Position: Q4 2016 in Review

Cadian Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 31,956 shares — an estimated $1.62M sold.

Cadian Capital Management first reported a position in NBIX in Q2 2015 and held it in 6 quarters. The position peaked at $28.3M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • Cadian Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • Cadian Capital Management sold 31,956 Neurocrine Biosciences shares in Q4 2016, an estimated $1.62M.
  • Cadian Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 6 quarters.
  • Cadian Capital Management's Neurocrine Biosciences position peaked at $28.3M in Q4 2015.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Cadian Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.